Th22 Cells Shape Colorectal Cancer Stemness Via Epigenetic Regulation (TUM2P.877)

Ilona Kryczek,Yanwei Lin,Nisha Nagarsheth,Dongjun Peng,Lili Zhao,Ende Zhao,Linda Vatan,Wojciech Szeliga,Yali Dou,Witold Zgodzinski,Marek Majewski,Grzegorz Wallner,Jingyuan Fang,Emina Huang,Weiping Zou
DOI: https://doi.org/10.4049/jimmunol.192.supp.71.1
2014-01-01
Abstract:Abstract Little is known about the direct impact of immune elements on human colorectal cancer invasiveness and stemness. We investigated the interaction between IL-22+ cells and cancer (stem) cells in colorectal cancer patients. We have demonstrated that Th22-derived IL-22 targets disruptor of telomeric silencing 1-like (DOT1L). DOT1L methylates histone 3 lysine 79 (H3K79) and, in turn, leads to core stem cell gene activation, resulting in increased colon cancer stemness and tumorigenic potential. In addition, increased levels of DOT1L and H3K79me2 in colorectal cancer predict poor patient survival. Collectively, this work identifies that Th22 cells control colon cancer stemness via epigenetic regulation that affects patient outcome. Efforts to target this network might be a strategy in treating patients with colorectal cancer.
What problem does this paper attempt to address?